Implantable CNS Drug Delivery Patent Snapshot 2026
Medtronic dominates this highly concentrated field, holding the majority of patent families among the top hundred filers, with device-based fluid-delivery apparatus forming the core technology route. Annual filing volume peaked in 2022 and has eased since, signaling a field past its most active growth phase even as new clinical entrants continue to emerge.
Medtronic leads a sharply concentrated applicant field
Medtronic Inc ranks first with 20 patent records, well ahead of second-ranked Lyra Therapeutics Inc at 7 and third-ranked Massachusetts Eye & Ear Infirmary at 4. The remainder of the ranked applicants each hold two or fewer patent records.
The top five filers collectively account for 95% of the combined total across the ranked applicants visible in this query — an unusually high concentration that reflects Medtronic’s long-standing incumbency in implantable intrathecal and intracerebral pump systems. The tier gap between Medtronic and all challengers is substantial.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | Medtronic Inc | 20 | |
| 2 | Lyra Therapeutics Inc | 7 | |
| 3 | MASSACHUSETTS EYE & EAR INFARY | 4 | |
| 4 | University of Massachusetts | 2 | |
| 5 | Incube Labs LLC | 2 | |
| 6 | Bexar Biomedical Inc | 1 | |
| 7 | Board of Regents of the University of Texas System | 1 |
Medtronic’s position implies that core device-delivery IP is effectively controlled by a single incumbent; challengers are pursuing differentiated angles in drug formulation (Lyra Therapeutics), surgical implant design (Massachusetts Eye & Ear Infirmary), and fluid-access interfaces (Incube Labs) rather than competing head-on in the pump-catheter core.
The most recent 18–24 months of filings are subject to publication lag and will likely show higher counts as pending applications publish; interpret any apparent trough in 2023–2025 with that caveat. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
Activity surged in 2022 then eased; fluid-delivery devices dominate the technology mix
Two charts together capture the temporal arc and the technology structure of this space: one tracks annual filing volume back to 2017, the other shows how IPC classes are distributed across the corpus.
Annual filing trend
Filings were essentially absent in 2017–2018, rose to 10 records in 2019, dipped through 2020–2021, then spiked sharply to 13 in 2022 before falling back. The 2023–2025 period appears sparse, but publication lag means actual 2024–2025 activity is likely under-reported; the 2022 peak is the verified high-water mark.
↗ Hover for values · click a bar to ask EurekaTechnology composition
A61M (Devices for body fluids, including infusion pumps and catheters) is by far the visible IPC class, reflecting the hardware-centric nature of implantable CNS delivery. A61K (Medicinal preparations) is the second largest branch, capturing drug formulation and carrier patents. A61F (Implants and prostheses) and A61B (Diagnosis and surgery) account for smaller but meaningful shares. A61N (Electrotherapy), A61L (Sterilization), and A61P (Therapeutic activity) are each sparsely covered.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Methods and compositions for central nervous syste…
The disclosure herein provides, in example embodiments, methods and compositions for central nervous system (CNS) drug delivery and treatment comprising administering an infusion solution to a cerebrospinal fluid (CSF) of the subject, wherein the infusion solution comprises a hypertonic solution. The disclosure also provides compositions comprising a… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Methods and apparatus for enhanced and controlled … | 166 |
| 2 | Methods and apparatus for enhanced and controlled … | 106 |
| 3 | Method of delivering drugs to specific regions of … | 96 |
| 4 | Method of delivering drug to brain via spinal cord | 60 |
| 5 | Reduction of inflammatory mass with spinal catheters | 52 |
| 6 | Method of delivering drug to brain via spinal cord | 51 |
| 7 | Trailing system for evaluation of the efficacy of … | 37 |
| 8 | Reduction of inflammatory mass with spinal catheters | 20 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
Assignee snapshot from the current evidence set
The applicants below are visible in this query result. Because the evidence set is relatively small, read this section as a directional snapshot rather than a full competitive ranking.
Medtronic Inc
Medtronic holds 20 patent records — more than twice the combined total of the next two ranked applicants. Its technology emphasis is concentrated in A61M fluid-delivery devices, spanning infusion pump components, catheter systems, and fluid-access ports. The breadth and depth of this coverage reflects decades of commercialized intrathecal drug-delivery products; no momentum data signals a recent acceleration, consistent with a mature incumbent consolidating rather than expanding its portfolio.
patent records: 20Lyra Therapeutics Inc
Lyra Therapeutics ranks second with 7 patent records and is flagged as a new entrant, indicating its filings are recent with no prior-period baseline for comparison. Its technology focus sits in A61K medicinal preparations, A61B surgical instruments, and A61F implants — a combination pointing to a bioresorbable or matrix-based drug-eluting implant strategy rather than active pump systems. This formulation-plus-implant approach targets white space the Medtronic device portfolio does not directly cover.
patent records: 7Frequently asked questions
Medtronic Inc leads with 20 patent records among the ranked applicants, more than double the next-ranked filer, Lyra Therapeutics Inc, which holds 7 patent records. The remaining applicants each hold four or fewer.
Annual filings were effectively zero in 2017–2018, rose to 10 records in 2019, dipped in 2020–2021, then peaked at 13 in 2022. Volume has eased since that peak, and the field is in a declining phase. The 2023–2025 apparent trough is partly a publication-lag artifact.
A61M (Devices for body fluids, including infusion pumps and catheters) is the visible class. A61K (Medicinal preparations) is second, followed by A61F (Implants and prostheses) and A61B (Diagnosis and surgery). A61N, A61L, and A61P each account for very small shares.
The United States is the primary jurisdiction with 20 patent records. Europe (EPO) follows with 8 records and WIPO (PCT) with 5. Canada and Austria each carry 2 records, and the United Kingdom carries 1.
Collaboration is sparse. The only identified co-filing relationship in the evidence is between Bexar Biomedical Inc and the Board of Regents of the University of Texas System, who jointly filed one patent record. Most applicants appear to be filing independently.
The most under-served adjacent branches relative to the visible A61M core are A61N (Electrotherapy and radiation therapy) and A61P (Therapeutic activity of compounds), each at only 2 patent records and 3% share. Hybrid stimulation-delivery systems and novel CNS drug-payload combination products represent the most technically plausible directions in these sparse branches.
Ready to map your own implantable CNS drug delivery Snapshot?
Join 18,000+ innovators using PatSnap Eureka to map any technology landscape: search 2B+ patents and papers, surface key assignees, and generate a report like this in minutes.
Disclaimer. This page is generated from PatSnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. PatSnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.